NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
NGEN is expected to report earnings to rise 262.00% to -7 cents per share on August 12
Q2'26
Est.
$-0.07
Q1'26
Beat
by $0.06
Q4'25
Missed
by $0.22
The last earnings report on May 18 showed earnings per share of -1 cents, beating the estimate of -7 cents. With 195.76K shares outstanding, the current market capitalization sits at 203.91M.